KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Gains from Investment Securities (2016 - 2025)

Amgen has reported Gains from Investment Securities over the past 17 years, most recently at -$2.0 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$2.0 million for Q4 2025, down 105.26% from a year ago — trailing twelve months through Dec 2025 was $32.0 million (down 81.92% YoY), and the annual figure for FY2025 was $32.0 million, down 81.92%.
  • Gains from Investment Securities for Q4 2025 was -$2.0 million at Amgen, up from -$22.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AMGN hit a ceiling of $355.0 million in Q4 2023 and a floor of -$492.0 million in Q3 2023.
  • Median Gains from Investment Securities over the past 5 years was $9.0 million (2025), compared with a mean of $10.5 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 16500.0% in 2021 and later surged 778.57% in 2024.
  • Amgen's Gains from Investment Securities stood at $28.0 million in 2021, then surged by 771.43% to $244.0 million in 2022, then skyrocketed by 45.49% to $355.0 million in 2023, then crashed by 89.3% to $38.0 million in 2024, then crashed by 105.26% to -$2.0 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$2.0 million (Q4 2025), -$22.0 million (Q3 2025), and $20.0 million (Q2 2025) per Business Quant data.